[Skip to Navigation]
Sign In
Comment & Response
August 26, 2021

Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity

Author Affiliations
  • 1European Medical Writers Association Special Interest Group Medical Communications
  • 2Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany
  • 3Ethics and Standards Committee, International Society for Medical Publication Professionals, Tarrytown, New York
  • 4Caudex, McCann Health Medical Communications Ltd, Oxford, United Kingdom
  • 5President, American Medical Writers Association, Rockville, Maryland
  • 6Encore Biomedical Communications LLC, Encinitas, California
JAMA Oncol. 2021;7(10):1578-1579. doi:10.1001/jamaoncol.2021.3341

To the Editor On behalf of 3 professional associations representing medical writers (MWs)—the American Medical Writers Association, the European Medical Writers Association, and the International Society for Medical Publication Professionals—we contest the remarks made about MWs by Del Paggio et al1 in their recent cohort study published in JAMA Oncology.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×